Company / CapEx per Share
Celldex Therapeutics, Inc. CapEx per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest CapEx per Share
$0.04
FY2025
5-year range
$0.03 / $0.04
FY2021-FY2025
Trend
+41.1%
vs FY2024
Sector context
#134 of 149
Health Care
What the data says
Among 149 Health Care companies, Celldex Therapeutics, Inc. is in the bottom 10% for capex per share. CapEx per Share returned to growth in FY2025 after 2 years of decline, reaching $0.04.
Based on SEC 10-K filings.
0.04 in FY2025 with a 5-year CAGR of +0.8%.
Improved from $0.03 to $0.04 over the past 2 years.
Health Care sector context is included.
CapEx per Share over time
Growth rates
- 3-Year CAGR
- +1.7%
- 5-Year CAGR
- +0.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 149This company $0.04 Sector average $1.68
▼
-97.6% below sector average
Key checks
Key Insights
- In FY2025, capex per share increased 41.1% year-over-year.
- Ranks #134 out of 149 companies in the Health Care sector.
- Peak capex per share was recorded in FY2018.
- Lowest capex per share in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | CapEx per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.04 | +41.1% |
| FY2024 | $0.03 | -11.1% |
| FY2023 | $0.03 | -16.0% |
| FY2022 | $0.04 | +44.9% |
| FY2021 | $0.03 | -31.8% |
| FY2020 | $0.04 | -9.0% |
| FY2019 | $0.04 | -85.5% |
| FY2018 | $0.30 | +1907.9% |
| FY2017 | $0.01 | -35.0% |
| FY2016 | $0.02 | -53.8% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026